Clinical Trial Search

Primary: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 — 62; 72; 49; 66.7 Percentage of participants — p=0.1155

Primary: Apneic Threshold (AT) and Carbon-dioxide (CO2) Reserve — 39.8; 36.7; -4.1; -2.6 mm Hg — p=<0.05

Primary: Injection Dispersal Patterns Measured (in cm) in the Superoinferior Directions on Post-injection MRI With a Calibrated Internal Measurement Software. — 14.73 cm

Primary: Change in rTNSS From Baseline to End of Treatment — 10.3; 10.4; 10.4; 10.3 units on a scale — p=<0.0001

Primary: Brief Pain Inventory (BPI) at Week 14 — 10.2; 9.7; 5.3; 5.1 units on a scale

Primary: Change (Increase) in Uncorrected Near Visual Acuity — 3.1 lines of visual acuity improvement

Primary: Lane Position Deviation — -1.25; -1.36; -1.22; -1.21 feet

Primary: Anti-tumor Effects of Imiquimod as Assessed by Modified World Health Organization (WHO) Criteria — 14; 5; 5; 3 Participants

Primary: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy — 1.36; 1.19; 1.34; 1.19 days — p=0.05

Primary: Incidence of Acute Graft-versus-host Disease (GVHD) — 44.7 percentage of participants

Primary: Treatment Success Based on Patient Report on Validated Questionnaire — 42 Participants

Primary: Overall Response Rate (CR+PR) Per Investigator Assessment Based on GOG-RECIST Criteria — 7; 4; 3; 14 Participants

Primary: C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool — 11; 6 Participants

Primary: Mean Clinical Administered PTSD Scale for DSM-IV (CAPS) Score — 31; 30; 20; 25 units on a scale

Primary: Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target Knee — 5.8; 5.9 units on a scale